p53 Arg72Pro Polymorphism Predicts Survival Outcome in Lung Cancer Patients in Indian Population

REFERENCES

• Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Dumont P., Leu J. I., Della P. A., III, George D. L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003; 33: 357–365
   PubMed Web of Science ®Google Scholar
• Birgander R., Sjalander A., Rannug A., Alexandrie A. K., Sundberg M. I., Seidegard J., Tornling G., Beckman G., Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995; 16: 2233–2236
   PubMed Web of Science ®Google Scholar
• Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996; 17: 1313–1316
   PubMed Web of Science ®Google Scholar
• Rosenthal A. N., Ryan A., Al Jehani R. M., Storey A., Harwood C. A., Jacobs I. J. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352: 871–872
   PubMed Web of Science ®Google Scholar
• Weston A., Perrin L. S., Forrester K., Hoover R. N., Trump B. F., Harris C. C., Caporaso N. E. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol. Biomarkers Prev. 1992; 1: 481–483
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993; 14: 1085–1089
   PubMed Web of Science ®Google Scholar
• Jin X., Wu X., Roth J. A., Amos C. I., King T. M., Branch C., Honn S. E., Spitz M. R. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995; 16: 2205–2208
   PubMed Web of Science ®Google Scholar
• Liu G., Miller D. P., Zhou W., Thurston S. W., Fan R., Xu L. L., Lynch T. J., Wain J. C., Su L., Christiani D. C. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res. 2001; 61: 8718–8722
   PubMed Web of Science ®Google Scholar
• Wu X., Zhao H., Amos C. I., Shete S., Makan N., Hong W. K., Kadlubar F. F., Spitz M. R. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J. Natl. Cancer Inst. 2002; 94: 681–690
   PubMed Web of Science ®Google Scholar
• Sambrook J., Frustaci S. Maniatis. Molecular Cloning A Laboratory Manual, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989
   Google Scholar
• Ara S., Lee P. S., Hansen M. F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990; 18: 4961
   PubMed Web of Science ®Google Scholar
• Sreeja L., Syamala V., Hariharan S., Madhavan J., Devan S. C., Ankathil R. Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J. Hum. Genet. 2005; 50: 618–627
   PubMed Web of Science ®Google Scholar
• Baptiste N., Prives C. p53 in the cytoplasm: a question of overkill?. Cell 2004; 116: 487–489
   PubMed Web of Science ®Google Scholar
• Fan R., Wu M. T., Miller D., Wain J. C., Kelsey K. T., Wiencke J. K., Christiani D. C. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2000; 9: 1037–1042
   PubMed Web of Science ®Google Scholar
• Irarrazabal C. E., Rojas C., Aracena R., Marquez C., Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett. 2003; 144: 69–76
   PubMed Web of Science ®Google Scholar
• Zhang J. H., Li Y., Wang R., Wen D. G., Wu M. L., He M. p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population. Zhonghua Zhong Liu Za Zhi 2003; 25(4)365–367
   PubMedGoogle Scholar
• Mechanic L. E., Marrogi A. J., Welsh J. A., Bowman E. D., Khan M. A., Enewold L., Zheng Y. L., Chanock S., Shields P. G., Harris C. C. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005; 26: 597–604
   PubMed Web of Science ®Google Scholar
• Sakiyama T., Kohno T., Mimaki S., Ohta T., Yanagitani N., Sobue T., Kunitoh H., Saito R., Shimizu K., Hirama C., Kimura J., Maeno G., Hirose H., Eguchi T., Saito D., Ohki M., Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int. J. Cancer 2005; 114: 730–737
   PubMed Web of Science ®Google Scholar
• Hu Y., McDermott M. P., Ahrendt S. A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin. Cancer Res. 2005; 11: 2502–2509
   PubMed Web of Science ®Google Scholar
• Szymanowska A., Jassem E., Dziadziuszko R., Borg A., Limon J., Kobierska-Gulida G., Rzyman W., Jassem J. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006; 52: 9–14
   PubMed Web of Science ®Google Scholar
• Papadakis E. D., Soulitzis N., Spandidos D. A. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br. J. Cancer 2002; 87: 1013–1018
   PubMed Web of Science ®Google Scholar
• Jain N., Singh V., Hedau S., Kumar S., Daga M. K., Dewan R., Murthy N. S., Husain S. A., Das B. C. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 2005; 128: 3999–4007
   PubMed Web of Science ®Google Scholar
• Toyooka S., Tsuda T., Gazdar A. F. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 2003; 21: 229–239
   PubMed Web of Science ®Google Scholar
• Wang Y. C., Lee H. S., Chen S. K., Chang Y. Y., Chen C. Y. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur. J. Cancer 1999; 35: 226–230
   PubMed Web of Science ®Google Scholar
• Wang Y. C., Chen C. Y., Chen S. K., Chang Y. Y., Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 1999; 5: 129–134
   PubMed Web of Science ®Google Scholar
• Nelson H. H., Wilkojmen M., Marsit C. J., Kelsey K. T. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26: 1770–1773
   PubMed Web of Science ®Google Scholar
• Marin M. C., Jost C. A., Brooks L. A., Irwin M. S., O'Nions J., Tidy J. A., James N., McGregor J M., Harwood C. A., Yulug I. G., Vousden K. H., Allday M. J., Gusterson B., Ikawa S., Hinds P. W., Crook T., Kaelin W. G., Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000; 25: 47–54
   PubMed Web of Science ®Google Scholar